Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 1
1932 1
1943 1
1946 3
1947 6
1948 6
1949 3
1950 12
1951 19
1952 14
1953 23
1954 16
1955 23
1956 39
1957 23
1958 25
1959 42
1960 33
1961 41
1962 47
1963 55
1964 59
1965 77
1966 61
1967 81
1968 106
1969 63
1970 78
1971 97
1972 89
1973 103
1974 128
1975 95
1976 120
1977 104
1978 114
1979 157
1980 181
1981 176
1982 189
1983 190
1984 209
1985 223
1986 233
1987 221
1988 237
1989 277
1990 272
1991 312
1992 326
1993 242
1994 320
1995 325
1996 302
1997 306
1998 338
1999 350
2000 339
2001 363
2002 353
2003 389
2004 479
2005 472
2006 546
2007 533
2008 585
2009 610
2010 610
2011 669
2012 730
2013 785
2014 738
2015 747
2016 839
2017 785
2018 864
2019 808
2020 949
2021 967
2022 390
Text availability
Article attribute
Article type
Publication date

Search Results

20,323 results
Results by year
Filters applied: . Clear all
Page 1
Pleural mesothelioma classification update.
Beasley MB, Galateau-Salle F, Dacic S. Beasley MB, et al. Virchows Arch. 2021 Jan;478(1):59-72. doi: 10.1007/s00428-021-03031-7. Epub 2021 Jan 21. Virchows Arch. 2021. PMID: 33475835 Review.
The 2015 WHO classification of pleural mesotheliomas includes three major histologic subtypes-epithelioid, sarcomatoid, and biphasic. ...The major change in the forthcoming WHO classification is the inclusion of mesothelioma in situ as a diagnostic category. In this …
The 2015 WHO classification of pleural mesotheliomas includes three major histologic subtypes-epithelioid, sarcomatoid, and biphasic. …
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA. Sinn K, et al. Curr Opin Oncol. 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. Curr Opin Oncol. 2021. PMID: 33186182 Review.
PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with still poor prognosis. ...
PURPOSE OF REVIEW: Malignant pleural mesothelioma (MPM) is a rare, but aggressive tumor with still poor prognosis. ...
How I treat malignant pleural mesothelioma.
Viscardi G, Di Liello R, Morgillo F. Viscardi G, et al. ESMO Open. 2020 Mar;4(Suppl 2):e000669. doi: 10.1136/esmoopen-2019-000669. ESMO Open. 2020. PMID: 32156681 Free PMC article. Review.
Malignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. ...
Malignant pleural mesothelioma is a rare and aggressive malignancy mostly associated with occupational asbestos exposure. ...
Diagnostic mesothelioma biomarkers in effusion cytology.
Eccher A, Girolami I, Lucenteforte E, Troncone G, Scarpa A, Pantanowitz L. Eccher A, et al. Cancer Cytopathol. 2021 Jul;129(7):506-516. doi: 10.1002/cncy.22398. Epub 2021 Jan 19. Cancer Cytopathol. 2021. PMID: 33465294 Review.
Malignant mesothelioma is a rare malignancy with a poor prognosis whose development is related to asbestos fiber exposure. ...The purpose of this review is to provide an essential appraisal of the literature regarding the diagnostic value of many of these emerging b
Malignant mesothelioma is a rare malignancy with a poor prognosis whose development is related to asbestos fiber exposure. ...
The Molecular Basis of Malignant Pleural Mesothelioma.
Wadowski B, De Rienzo A, Bueno R. Wadowski B, et al. Thorac Surg Clin. 2020 Nov;30(4):383-393. doi: 10.1016/j.thorsurg.2020.08.005. Epub 2020 Sep 12. Thorac Surg Clin. 2020. PMID: 33012428 Free PMC article. Review.
Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural lining associated with asbestos exposure in greater than 80% of cases. ...
Malignant pleural mesothelioma (MPM) is a rare, aggressive malignancy of the pleural lining associated with asbestos exposure
Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma.
Tang TT, Konradi AW, Feng Y, Peng X, Ma M, Li J, Yu FX, Guan KL, Post L. Tang TT, et al. Mol Cancer Ther. 2021 Jun;20(6):986-998. doi: 10.1158/1535-7163.MCT-20-0717. Epub 2021 Apr 13. Mol Cancer Ther. 2021. PMID: 33850002
Mutations in the neurofibromatosis type 2 (NF2) gene that limit or abrogate expression of functional Merlin are common in malignant mesothelioma. Merlin activates the Hippo pathway to suppress nuclear translocation of YAP and TAZ, the major effectors of the pathway …
Mutations in the neurofibromatosis type 2 (NF2) gene that limit or abrogate expression of functional Merlin are common in malignant
Pleural mesothelioma classification-update and challenges.
Dacic S. Dacic S. Mod Pathol. 2022 Jan;35(Suppl 1):51-56. doi: 10.1038/s41379-021-00895-7. Epub 2021 Aug 31. Mod Pathol. 2022. PMID: 34465883 Review.
Mesothelial tumors are classified into benign or preinvasive tumors, and mesotheliomas. The benign or preinvasive group includes adenomatoid tumors, well-differentiated papillary mesothelial tumors, and mesothelioma in situ. Malignant tumors are mesothelio
Mesothelial tumors are classified into benign or preinvasive tumors, and mesotheliomas. The benign or preinvasive group includes aden …
An overview of existing mesothelioma registries worldwide, and the need for a US Registry.
van Gerwen M, Alpert N, Flores R, Taioli E. van Gerwen M, et al. Am J Ind Med. 2020 Feb;63(2):115-120. doi: 10.1002/ajim.23069. Epub 2019 Nov 7. Am J Ind Med. 2020. PMID: 31701555 Review.
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well established; this has prompted several countries to establish mesothelioma epidemiologic surveillance programs often at the request of nationa …
The association between asbestos exposure, mainly in occupational settings, and malignant mesothelioma has been well establish …
20,323 results
You have reached the last available page of results. Please see the User Guide for more information.